Pipeline
Fueled by its deep scientific understanding built over decades of research in protein misfolding, Prothena seeks to fundamentally change the course of grave or currently untreatable diseases associated with this biology. Our antibody-based therapeutic candidates are in development for the potential treatment of a number of indications, including Parkinson’s disease (PRX002/RG7935), and ATTR amyloidosis (PRX004). We continue to advance additional discovery programs against targets including tau, Aβ (Amyloid beta) and ALECT2 by leveraging our deep scientific understanding of disease pathology.
PRX002/RG7935 is currently in a Phase 2 study in patients with early Parkinson’s disease. Prothena continues to generate additional novel antibodies and plans to advance PRX004 for the potential treatment of ATTR amyloidosis into Phase 1 clinical development.
Tau
AD, PSP, FTD, CTE
Aβ
AD
TDP-43
ALS, FTD
Undisclosed
Neurodegeneration
